Efficacy and safety of preoperative antibacterial agent on infection after endoscopic treatment of esophagogastric varices in liver cirrhotic patients: a prospective randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024830

Enrollment

Unknown

Registered

2019-07-29

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophagogastric varices in liver cirrhotic

Interventions

experimental group:cefuroxime

control group:cefotaxime sodium and sulbactan sodium

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) cirrhosis patients , child-pugh A or B grade; (2) gastroscopy confirmed the presence of moderate and severe esophagogastric varices, and it was suitable for patients receiving EIS treatment; (3) primary prevention or secondary prevention.

Exclusion criteria

Exclusion criteria: (1) predominant ascitespatients; (2) emergency endoscopic treatment of patients; (3) there were signs of infection, and there was a history of using antibacterial drugs one week before receiving EIS treatment; (4) endoscopic treatment contraindications in patients; (5) patients with hypersensitivity to cephalosporin; (6) refuse to sign the informed consent patients.

Design outcomes

Primary

Measure	Time frame
whole blood cell analysis;	—

Countries

China

Contacts

Public ContactQiu Xinye

Beijing You'an Hospital, Capital Medical University

qiuxinye@163.com+86 18210156518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026